Shares of Novo Nordisk dropped over 24% after disappointing results in a trial for its CagriSema weight loss drug, which fell short of expectations with a 22.7% weight reduction. The stock recovered slightly to trade down 18.8%, while rival Eli Lilly’s obesity drug saw a 5% rise. Novo plans to further explore CagriSema’s potential after outperforming Wegovy in weight loss, with regulatory submission expected by 2025.
Full Article
House Democrats release lewd birthday message Trump allegedly sent to Jeffrey Epstein
House Democrats shared an alleged birthday card from Donald Trump to Jeffrey Epstein from 2003, which Trump denies sending, claiming it was part of a book compiled by Epstein's associate Ghislaine Maxwell. The card features a provocative drawing and a conversation about shared interests, amidst ongoing scrutiny of Epstein's estate and the investigation into his sex trafficking activities. Want More Context? 🔎
Read more